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INTRODUCTION 28 
It is widely accepted that most vulvar squamous cell carcinomas (VSCC) 29 
originate from intraepithelial lesions that precede the development of VSCC by 30 
a variable period of time 1–3. Each type of VSCC, i.e., human papillomavirus 31 
(HPV)-associated and HPV-independent, not only has particular histologic 32 
features but is also associated with a distinct type of intraepithelial lesion 3. 33 
Thus, HPV-associated VSCCs are usually of basaloid, warty or non-keratinizing 34 
subtype and arise from high-grade intraepithelial lesions, also referred to as 35 
vulvar intraepithelial neoplasia of usual type (HSIL/uVIN), which have basaloid 36 
or warty features. In contrast, HPV-independent VSCCs, which are usually of a 37 
keratinizing subtype, derive from a premalignant lesion named differentiated 38 
vulvar intraepithelial neoplasia (dVIN) and are frequently associated with 39 
chronic inflammatory lesions, especially lichen sclerosus (LS) 1,2. However, this 40 
correlation between histological features and HPV involvement is not always the 41 
rule, and there is increasing evidence of a frequent overlap between HPV status 42 
and the histological characteristics of VSCC 3–6. Thus, the presence of 43 
keratinizing, basaloid, warty features or koilocytotic changes is highly unreliable 44 
to classify the tumor as HPV-associated or HPV-independent 5. The problem is 45 
further stressed by the occasional overlap between the premalignant lesions, as 46 
in a small percentage of cases the precursors of HPV-independent VSCC may 47 
closely simulate HSIL/uVIN 7,8. A recent meta-analysis has estimated that the 48 
pooled prevalence of HPV-related dVIN-like lesions is about 2% 9. However, no 49 
study has specifically addressed the description of these dVIN-like 50 
intraepithelial lesions in HPV-associated VSCC. 51 
In this study, we aimed to evaluate adjacent intraepithelial lesions in a 52 
large series of 326 VSCC positive for DNA HPV, focusing on unusual 53 
histological patterns such as intraepithelial lesions resembling dVIN and/or LS, 54 
the skin lesions typically related to HPV-independent VSCC. We analyzed their 55 
correlation with the HPV DNA genotype, p16 immunohistochemistry, and HPV 56 
mRNA. 57 
MATERIAL AND METHODS 58 
Case selection  59 
We reviewed a series of 1709 invasive VSCCs included in the VVAP study 60 
(International Survey on HPV prevalence and type distribution in vulvar, vaginal, 61 
anal, penile neoplasia) coordinated by the Catalan Institute of Oncology (ICO, 62 
Barcelona-Spain) in collaboration with DDL Diagnostics Laboratory (Rijswijk, the 63 
Netherlands)10.  64 
We selected all cases fulfilling the following inclusion criteria: (1) invasive 65 
squamous carcinoma identified in the block; (2) adequate material for 66 
histological analysis, HPV detection and typing, and p16 immunohistochemical 67 
staining; (3) a positive result for HPV detection by polymerase chain reaction 68 
(PCR); and (4) the presence at least 1 cm of skin adjacent to the invasive 69 
tumor. The study was approved by the local and ICO Ethics Committees. Three 70 
hundred twenty-six cases fulfilled the inclusion criteria.  71 
Tissue preparation, nucleic-acid isolation and HPV DNA detection  72 
DNA extraction was performed on whole sections of formalin-fixed 73 
paraffin-embedded (FFPE) tissue from surgical specimens or vulvar biopsies as 74 
previously described 5,10. Sectioning and sample preparation were carried out 75 
with the highest safety measures to avoid cross-contamination. Processing and 76 
pathology diagnosis were done by the ICO laboratory. 77 
HPV DNA detection was performed using SPF10 PCR, DEIA and the 78 
LiPA25 system (version 1, Laboratory Biomedical Products, Rijswijk, The 79 
Netherlands) as previously described 5,10. Each run contained negative and 80 
positive controls to monitor the efficiency of DNA isolation, PCR amplification, 81 
hybridization, and genotyping procedures.  82 
E6*I mRNA reverse transcription (RT-)PCR   83 
 Extraction and HPV mRNA detection from tissue ribbons were performed 84 
as previously described 5,11. For each case, HPV type-specific E6*I mRNA RT-85 
PCR assays were performed for the HPV type(s) determined previously by 86 
genotyping and for a cellular ubiquitin C gene as a control for tissue quality. 87 
HPV E6*I mRNA assays were developed for the following HPV types: 16, 18, 88 
26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 70, 73, and 82. A 89 
second assay was performed to assess the presence of HPV16 E6*I mRNA in 90 
all cases, irrespective of the HPV DNA result.  91 
HPV mRNA extraction and detection was not performed in 22 cases in 92 
which low-risk or undetermined HPV types were detected. Thus, HPV mRNA 93 
results were available in 304 out of the 326 cases. 94 
p16 immunohistochemistry 95 
 All tumors were stained with p16 monoclonal antibody using the CINtec 96 
Histology Kit (clone E6H4; Roche-mtm-Laboratories, Heidelberg, Germany) 12. 97 
Only cases showing strong and diffuse block staining of the basal and 98 
suprabasal layers were considered as positive (p16 upregulation) 13. The p16 99 
staining was evaluated independently in the invasive tumor, in the intraepithelial 100 
lesion/s and in the normal skin. 101 
Classification of the lesions as conclusively and non-conclusively 102 
associated with HPV  103 
A case was classified as conclusively associated with HPV when it was 104 
positive for HPV DNA in the invasive tumor and had either a positive staining for 105 
p16 immunohistochemistry, was positive for HPV mRNA or both. Non-106 
conclusive association with HPV was defined as the identification of HPV DNA 107 
in the invasive tumor with negative staining for p16 immunohistochemistry and a 108 
negative result for HPV mRNA. Tumors in which only a low-risk or an 109 
undetermined HPV type were identified were analyzed independently, as HPV 110 
mRNA assays were not developed for these viruses.  111 
Histological evaluation 112 
A single histological slide of each case was available for review. 113 
Histological evaluation was blind to HPV DNA and genotyping, HPV mRNA, and 114 
p16 immunohistochemistry results. Invasive squamous carcinoma was 115 
confirmed in all the 326 cases. The VSCC were classified into keratinizing, 116 
basaloid, warty or non-keratinizing subtypes following the WHO 2014 117 
classification 14.  118 
The squamous epithelium adjacent to the neoplasms was carefully 119 
evaluated in search of associated pathology. In order to establish the diagnosis 120 
of intraepithelial lesion, the lesion had to be present at least 10 mm away from 121 
the invasive carcinoma to rule out possible peripheral intraepithelial extension 122 
simulating HSIL/uVIN or dVIN.  The adjacent HSIL/uVIN was classified as a 123 
basaloid or warty subtype. Briefly, the basaloid type HSIL/uVIN was 124 
characterized by small atypical cells throughout the whole epidermis with a 125 
striking architectural disarray 2. Warty type HSIL/uVIN was diagnosed when the 126 
epidermis had wide and deep rete ridges, clear pleomorphism and easily 127 
recognizable koilocytotic-like changes suggestive of HPV infection 3. dVIN-like 128 
lesion was defined by the presence of atypical keratinocytes limited to the basal 129 
and parabasal layers in the context of a fully differentiated epithelium 3. LS-like 130 
lesions were diagnosed in cases where homogenization of the collagen was 131 
clearly evident, alongside other features described elsewhere 1. The adjacent 132 
skin was considered normal in the absence of HSIL/uVIN, dVIN-lke lesions, 133 
and/or LS-like changes.  134 
RESULTS 135 
The adjacent skin was normal in 121/326 VSCC (37.1%), whereas 136 
205/326 (62.9%) showed at least one intraepithelial precursor lesion in the 137 
adjacent skin. HSIL/uVIN (warty or basaloid type) was observed as the only 138 
precursor lesion in 191 out of 326 tumors (58.6%). Unusual intraepithelial 139 
lesions, i.e. dVIN- and/or LS-like lesions, were identified in the adjacent skin in 140 
14 tumors (4.3%). Figure 1 shows the study algorithm. Table 1 shows the 141 
associated lesions identified in the skin for each specific HPV type in the whole 142 
series of 326 cases.  143 
The HPV mRNA results were available in 304 out of the 326 tumors 144 
included in the series.  Overall, 281/304 VSCC in which all the tests (HPV DNA, 145 
HPV mRNA and p16 results) were available, were considered as conclusively 146 
associated with high-risk HPV. Among the VSCC conclusively associated with 147 
HPV, 261 (92.9%) were positive for both p16 and HPV mRNA, 11 (3.9%) were 148 
positive only for p16, and 9 (3.2%) were positive only for HPV mRNA. Twenty-149 
four tumors were considered as non-conclusively associated with HPV due to 150 
negative p16 and HPV mRNA results. One hundred and eighty-seven of the 281 151 
(66.5%) tumors conclusively associated with HPV showed HSIL/uVIN in the 152 
adjacent skin, whereas only 3/24 (12.5%) of the tumors with a non-conclusive 153 
association had adjacent HSIL/uVIN lesions (p<0.001). The skin precursor was 154 
also positive for p16 in all the p16 positive tumors showing HSIL/uVIN.  155 
 Among the 21 tumors with a low-risk or undetermined HPV type 156 
identified, one with a low-risk HPV (HPV44) had adjacent HSIL/uVIN, with both 157 
the invasive tumor and the HSIL/uVIN being negative for p16. Two tumors with 158 
an HPV of undetermined type showed adjacent HSIL/uVIN and were positive for 159 
p16.  160 
Unusual intraepithelial lesions 161 
Fourteen samples showed unusual intraepithelial lesion adjacent to the 162 
DNA HPV-positive VSCC. Seven cases (7/326; 2.1%) showed dVIN-like 163 
features, 5 cases (1.5%) showed adjacent LS-like lesions, and in 2 cases 164 
(0.6%) dVIN- and LS-like lesions were identified simultaneously. Finally, in one 165 
case (0.3%) LS-like features were identified in combination with typical 166 
HSIL/uVIN. Table 2 shows the age, the results of the p16 immunohistochemistry 167 
study of the tumor and the precursor lesion and HPV mRNA, the other 168 
associated skin lesions and the histological sub-typing of the invasive tumor of 169 
all the cases with dVIN-like, LS-like or both lesions.  170 
Six cases were conclusively associated with HPV (3 dVIN-like lesions, 2 171 
LS-like lesions, 1 with combined dVIN/LS-like lesions). All were associated with 172 
HPV16 and were positive for both p16 and HPV mRNA. In all cases, the p16 173 
was also positive in the adjacent dVIN-like lesion. Similarly, in the three cases 174 
with LS-like lesions, the skin overlying the LS-like area showed block positivity 175 
for p16, at least focally.  176 
Another group of eight cases consisted of tumors with non-conclusive 177 
association with HPV and tumors caused by low-risk or undetermined HPV.  All 178 
were positive for HPV DNA but were negative for p16 both in the tumor and in 179 
the precursor lesions. In all these cases, the HPV mRNA was either negative or 180 
not tested.  181 
dVIN-like and LS-like lesions in tumors conclusively associated with HPV 182 
In all dVIN-like cases identified in tumors conclusively associated with 183 
HPV, atypical keratinocytes were identified in a fully differentiated epithelium, 184 
with atypia strictly limited to the basal and parabasal layers, and with cells 185 
having abundant eosinophilic cytoplasm (Figure 2 A and 2B). The epithelium 186 
was atrophic or acanthotic with superficial parakeratosis. The rete ridges were 187 
elongated and branched. The keratinocytes in the epidermis were enlarged, had 188 
prominent desmosomes, abundant eosinophilic cytoplasm, large vesicular 189 
nuclei and macronucleoli. No extension to skin appendages was identified. 190 
None of these cases had the typical whole epithelial thickness architectural 191 
disarray, prominent cytologic atypia and nuclear pleomorphism typical of 192 
HSIL/uVIN. A moderate lymphocytic infiltrate was present in the papillary 193 
dermis. In all cases, p16 showed diffuse block staining in the dVIN-like lesion 194 
with nuclear and cytoplasmic positivity involving at least the basal and 195 
suprabasal layers (Figure 2A’ and 2B’).  196 
 LS-like changes were characterized by broad condensation and 197 
hyalinization of the dermal collagen in the papillary dermis (Figure 3 A). The 198 
epidermis showed slight to moderate hyperkeratosis. In contrast with typical LS 199 
lesions the rete ridges appeared elongated. In the two cases, p16 showed 200 
diffuse block staining in the epithelium overlying the hyalinized dermal collagen 201 
(Figure 3A’). A case showed combined LS-like (hyalinization of the dermal 202 
collagen in the papillary dermis) and dVIN-like lesions (atypia limited to the 203 
basal and parabasal layers in a fully differentiated epithelium with elongated 204 
rete ridges) (Figure 3B).  The epithelium showed block positivity for p16. 205 
DISCUSSION 206 
In this study, we confirm that a subset of VSCC conclusively associated 207 
with HPV arises on intraepithelial lesions that have dVIN-like morphological 208 
features. In a subset of these cases, the association with HPV was conclusively 209 
established by positive HPV DNA result as well as the detection of HPV mRNA 210 
and a positive p16 result. Interestingly, in all these lesions p16 211 
immunohistochemistry showed “block positivity”, both in the invasive tumor and 212 
in the intraepithelial lesion, a characteristic finding in HSIL/uVIN lesions. These 213 
findings indicate that HSIL/uVIN could have a wider morphological spectrum 214 
than traditionally accepted, with some lesions having a dVIN-like morphology.  215 
The proportion of these cases was very low, as this morphology was identified 216 
in only four out of 281 tumors conclusively associated with HPV (1.4%). 217 
However, this distinction may be clinically relevant as vulvar HSIL/uVIN has a 218 
low progression potential and may regress spontaneously 15-17, whereas dVIN 219 
has shown a high potential for malignant transformation 8,18. Moreover, the 220 
identification of dVIN-like areas at the periphery in a VSCC may be considered 221 
as indirect evidence of an HPV-independent vulvar cancer 19. Interestingly, most 222 
of the women with VCSS conclusively associated with HPV with dVIN-like 223 
lesions were relatively old, a clinical characteristic typical of HPV-independent 224 
lesions. 225 
This unusual pattern of HSIL/uVIN has not specifically been described 226 
previously. Nevertheless, a thorough review of the literature identified two 227 
possible additional cases. Yang et al 20 analyzed 12 cases of dVIN by PCR 228 
and/or ISH for various HPV types, and identified one case positive for HPV type 229 
31/35/51 by in situ hybridization. The lesion was negative for p53 230 
immunohistochemistry and the patient had multifocal intraepithelial lesions, 231 
some of which showed histological features overlapping with HSIL/uVIN. 232 
Similarly, Haefner et al. identified HPV in 1 out of 7 cases of dVIN tested by 233 
PCR and in situ hybridization 21. Finally, a recent meta-analysis has estimated 234 
that the pooled prevalence of HPV-related dVIN-like lesions is about 2% 9. 235 
The existence of HSIL/uVIN lesions with dVIN-like histological features is 236 
not surprising, because morphology studies have shown clear limitations in 237 
classifying vulvar tumors as HPV-associated or -independent 3–6. Additionally, 238 
we have previously described that a small percentage of HPV-independent 239 
VSCC have adjacent intraepithelial lesions with histological features mimicking 240 
basaloid type HSIL/uVIN 4,7. Finally, a number of studies have reported 241 
occasional lesions with overlapping morphological features of HSIL/uVIN and 242 
dVIN; although most include either HPV-independent tumors or HPV detection 243 
was not made or was not reliable 8,20,22.  244 
In our study we found a strong correlation between the presence of high-245 
risk viral type and adjacent HSIL/uVIN, which was present in 66.8% of the 246 
tumors. These results are in keeping with previous studies describing a strong 247 
association between high-risk viral type HSIL/uVIN and VSCC 4,19,23. The 248 
percentage of HSIL/uVIN was similar for all tumors conclusively associated with 249 
HPV independently of the high-risk HPV type (and also with multiple infections) 250 
and ranged between 40-70%. In contrast, the percentage of HSIL/uVIN in 251 
tumors in which low-risk or undetermined HPV were detected was very low. 252 
The low percentage of tumors non-conclusively associated with HPV 253 
(positive for HPV DNA, but negative for both p16 and HPV mRNA) that were 254 
associated with HSIL/uVIN was of note in our study. These findings suggest that 255 
many of these cases represent false positives for HPV DNA and are in keeping 256 
with the previously proposed criteria that HPV DNA alone should not be 257 
considered as sufficient evidence of HPV-association, unless a second marker 258 
(p16 or HPV mRNA) is also detected 5,10. The almost constant positivity for p16 259 
both in the invasive tumor and the intraepithelial lesion indicates that this 260 
marker can confidently be used as an HPV surrogate 4,5,10. 261 
The presence of LS-like changes in 3 tumors conclusively associated with 262 
HPV (2 cases with LS-like lesions and 1 with coincident dVIN/LS-like lesions) is 263 
striking.  Although this coincidence could be largely circumstantial, and a 264 
woman with LS can be infected with HPV and also develop HSIL/uVIN, and 265 
subsequently, basaloid or warty VSCC, the block positivity for p16 in the skin 266 
overlying the LS-like lesions in all 3 tumors, even in skin with no atypical 267 
features, raises the question of the presence of LS features in some HPV-268 
associated intraepithelial lesions or the possible implication of HPV in the 269 
development of LS. A few studies have reported the presence of HPV in the 270 
epithelium with LS changes 24 in HPV-associated VSCC, and it seems that 271 
these cases have fewer mutations than conventional HPV-negative LS 25.  272 
The pathogenesis of the VSCC in which low risk (HPV44) or undetermined 273 
HPV was detected type is uncertain. Although HPV44 is infrequent and 274 
considered to be of a low-risk viral type, it has occasionally been linked to the 275 
development of anogenital carcinomas through different mechanisms, without 276 
p16 overexpression 26. However, the role of this HPV type is not well 277 
understood. To date, only one case of vulvar carcinoma of warty/basaloid 278 
morphology, in which HPV44 was detected, has been reported 26.  279 
The main limitation of the present series is that HPV DNA or mRNA was 280 
only analyzed in the whole paraffin block containing both the precursor and the 281 
invasive tumor. Consequently, the possibility of a dVIN lesion, not related to the 282 
tumor, growing in the vicinity of a VSCC conclusively associated with HPV 283 
cannot be completely ruled out. However, the diffuse “block staining” for p16 284 
identified in the dVIN-like lesions indicates that this hypothesis is rather unlikely. 285 
A second limitation is that we did not study p53, which is frequently positive in 286 
dVIN 20. Nevertheless, in most of our cases a clear association with HPV16 was 287 
demonstrated and the dVIN-like lesions showed clear staining for p16, an 288 
unusual feature in HPV-negative dVIN 27.  289 
In conclusion, in this large series of HPV-positive VSCCs with adjacent 290 
skin we found that a small proportion of tumors conclusively associated with 291 
HPV may arise in intraepithelial lesions that closely simulate dVIN and LS, the 292 
intraepithelial precursors of HPV-independent VSCC. Awareness of this unusual 293 
feature may help to correctly classify these lesions as HPV-associated. In 294 
addition, p16 staining is an excellent surrogate marker of HPV infection 28 and 295 
may help to identify these infrequent lesions. 296 
 297 
 298 
  299 
FIGURE LEGENDS  300 
Figure 1. Study algorithm 301 
 302 
Figure 2. Differentiated vulvar intraepithelial neoplasia-like (dVIN-like) changes 303 
in two cases conclusively associated with human papillomavirus (HPV) type 16. 304 
Atypical keratinocytes are identified in a fully differentiated epithelium, with 305 
atypia limited to the basal and parabasal layers. The rete ridges are elongated 306 
and branched. The keratinocytes in the epidermis have abundant eosinophilic 307 
cytoplasm, and vesicular nuclei with macronucleoli. The whole epithelial 308 
thickness architectural disarray, prominent cytologic atypia and nuclear 309 
pleomorphism typical of high-grade squamous intraepithelial lesion (HSIL/uVIN) 310 
are absent. p16 immunohistochemistry shows block positive staining (A, A’ case 311 
number 1; B and B’ case number 3) (A and B, hematoxylin and eosin stain; A’ 312 
and B’ p16 immunohistochemical stain). 313 
  314 
Figure 3. (A) Lichen sclerosus (LS)-like features in case number 5. There is 315 
clear condensation and hyalinization of the dermal collagen in the papillary 316 
dermis and subjacent inflammatory infiltrate. No atypical keratinocytes are 317 
identified. p16 shows block staining involving the whole thickness of the 318 
epithelium. Human papillomavirus (HPV) type 16 was identified (A’). 319 
(B) Case number 4 showing combined dVIN/LS-like lesions (case positive for 320 
HPV16). Hyalinization of the dermal collagen in the papillary dermis with 321 
subjacent inflammatory infiltrate coexists with elongation of the rete ridges and 322 
slight atypia of the basal layer. p16 immunohistochemistry shows block positive 323 
staining (B’) 324 
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